Rethinking Drug Commercialization: Navigating a Shifting Biotech Investment Landscape

Susanne brings a wealth of experience to her role in leading a global team of precision medicine industry experts dedicated to enhancing the testing ecosystem to help patients capitalize on new breakthrough personalized medications. Susanne's journey in molecular pathology has been marked by notable achievements, including spearheading several global launches of companion diagnostic products. As a leading author of the Practice Gaps Study, Susanne played a pivotal role in identifying 7 key clinical Practice Gaps contributing to patient leakage, and her impactful contributions to the field have earned her a well-deserved place among the PharmaVoice 100 list of transformational leaders in life sciences.

Rebecca Fryer is the Head of Commercial Partnerships at Diaceutics, where she leads the Diaceutics Precision Commercialization Incubator. In this role, Rebecca focuses on advancing and refining the company's precision commercialization strategy and offerings. With a robust background in health and life sciences consulting, she has extensive experience in leading the development of complex corporate strategies and implementing strategic change programs for health providers and biopharma. At Diaceutics, Rebecca works hand in hand with customers to develop insight-led, targeted, and commercially attractive commercialization models. Rebecca is passionate about improving testing, treatment adoption, and ultimately patient outcomes, ensuring that diagnostically enabled therapies reach their full potential.

Jose Jaime “JJ” Ferrer is Head of Precision Medicine, Strategy & Commercialization at Merus N.V., where he leads cross-functional efforts to advance precision oncology assets and drive commercial success. A proven leader in the biopharmaceutical industry, JJ has over 20 years of experience launching innovative therapies across oncology and rare diseases.

At Merus, JJ recently spearheaded the successful launch of Bizengri, the company’s first commercial product, establishing critical foundations for future growth. Prior to Merus, he played a pivotal role in the launch of VITRAKVI—the first tumor-agnostic therapy approved globally—during his time at Bayer Pharmaceuticals. Earlier in his career at Bristol Myers Squibb, JJ held senior commercial and marketing leadership roles, supporting the launch and commercialization of key oncology, immunology, hematology, and virology therapies.

Known for his strategic vision, data-driven approach, and passion for patient impact, JJ consistently builds and leads high-performing teams to bring breakthrough therapies to patients in need.

Matt Mancuso is a Managing Director and Partner in the Boston office of L.E.K. Consulting, where he heads the Life Sciences practice’s data- and analytics-driven work in pharmaceuticals. For more than a decade, he has guided biopharma clients on corporate, franchise, and innovation strategy, consistently uncovering new value. Matt excels at fusing scientific, clinical, and financial data into clear, actionable insights that accelerate growth and decision-making.